When was PathXL founded?

PathXL was founded in 2004 and raised its 1st funding round 5 years after it was founded.

Where is PathXL located?

PathXL is headquartered in Belfast, United Kingdom.

Which legal entities is PathXL associated with?

PathXL is associated with CIRDAN IMAGING LIMITED and 1 other.

Is PathXL a funded company?

PathXL is a funded company, having raised a total of $1.48M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 05, 2009.

When was the latest funding round of PathXL?

PathXL's latest funding was a $***** Series B round on Nov 13, 2012, with participation from 5 investors.

Where does PathXL rank among its competitors?

PathXL ranks 124th amongst 825 active competitors, of which 91 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of PathXL?

PathXL's top competitors include Exact Sciences, Ovation and GRAIL. Among them, GRAIL secured the most recent funding round in June, 2026.

PathXL - 2026 Company Profile, Team, Funding & Competitors

Company Details

Develops web-based workflow solutions for digital pathology. It provides solutions for path laboratory management, image storage and management, quality control, basic E image analysis, and whole slide scoring for biomarker discovery. In addition, the company has an exclusive agreement with Indica Labs for their Halo image analysis software. The primary focus is tumor analysis for oncology.

Website: pathxl.com
Social
Part Of

Key Metrics

Founded Year

2004

Location

Belfast, United Kingdom

Stage

Acquired

Total Funding

$1.48M in 3 rounds

Latest Funding Round

Series B, Nov 13, 2012, $*****

Investors

Par Equity & 7 more

Ranked

124^th among 825 active competitors

Similar Companies

Exact Sciences & 1044 more

Exit Details

Acquired by Philips (Jun 21, 2016)

View PathXL's full profile

PathXL is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CIRDAN IMAGING LIMITED CIN: NI603247 , United Kingdom, Active	May 24, 2010	£1M - £10M (As on Jun 30, 2022)	101 (As on Jan 31, 2022)
PHILIPS DCP (BELFAST) LIMITED CIN: NI049504 , United Kingdom, Active	Feb 02, 2004	-	-

PathXL got acquired by Philips on Jun 21, 2016.

Click here to take a look at PathXL's acquisition in detail

PathXL has raised a total funding of $1.48M over 3 rounds. Its first funding round was on Apr 05, 2009. Its latest funding round was a Series B round on Nov 13, 2012 for $*****. 5 investors participated in its latest round. PathXL has 8 institutional investors.

Here is the list of recent funding rounds of PathXL:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2012	9853319	Series B	3563606	1745591	4355653	6574837
Jan 20, 2012	1060956	Series A	6151264	9768304	2786177	E-Synergy
Apr 05, 2009	3988231	Seed	6784252	9111896	7908855	Crescent Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of PathXL's funding rounds and investors

The founders of PathXL is Peter Hamilton.

Here are the details of PathXL's key team members:

Peter Hamilton: Founder of PathXL and founder of 1 other company.
Des Speed: ex-CEO of PathXL. They are also an angel investor in 1 startup.

View details of PathXL's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PathXL include Exact Sciences, Ovation and GRAIL. Here is the list of Top 10 competitors of PathXL, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
2nd	Ovation 2009, Cambridge (United States), Series B	Provider of a cloud-based laboratory information and data management platform for researchers and clinicians	$33.3M	SignalFire, Madrona & 8 others	70/100
3rd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
4th	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
5th	Deciphex 2017, Dublin (Ireland), Series C	Network of pathologists providing digital diagnostic services for medical testing	$56.6M	Seroba Life Sciences, Molten Ventures & 13 others	65/100
6th	Cirdan Imaging 2010, Lisburn (United Kingdom), Series B	Laboratory Information System for clinical laboratories	$27.6M	Invest Northern Ireland, Kernel Capital & 41 others	65/100
7th	Quartzy 2009, Hayward (United States), Series C	Provider of web-based platform for labs management	$56.9M	Eminence Capital, Orthogonal Thinker & 20 others	64/100
8th	Labforward 2013, Berlin (Germany), Acquired	Laboratory data, devices, and researchers collaboration platform	$10.2M	IBB Ventures, Vogel Communications Group ... & 13 others	61/100
9th	Uncountable Data 2016, San Francisco (United States), Series A	Developer of a unified platform for research and development data management	$27M	Sageview Capital, MK Capital & 4 others	61/100
10th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
124th	PathXL 2004, Belfast (United Kingdom), Acquired	Develops web-based workflow solutions for digital pathology	$1.48M	Qubis, Co-Fund NI & 6 others	33/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on PathXL's competitors? Click here to see the top ones

Founders own 25.30%, Funds (largest shareholder) own 61.40%, Enterprises own 1.90% and Angels own 10.01%. The net worth of PathXL's founders is INR 3.03M as of Dec 18, 2015.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	25.30%	3.03M	1633872	7312504	6684395	2707875
Fund	61.40%	7.31M	5952442	3967655	9630205	1361087
Invest Northern Ireland	8754718	2137432	5420769	7408705	7765530	4057483
Enterprise	1.90%	223K	4	4	1	1
Angel	10.01%	1.19M	4559751	3323055	8405792	5275694
Other People	1.30%	159K	8	5	7	6
Total	99.91%	1.19Cr	1296970	7064643	4680275	6751254